| Trial ID: | L0056 |
| Source ID: | NCT04642261
|
| Associated Drug: |
Empagliflozin
|
| Title: |
Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic Fatty Liver Disease
|
| Interventions: |
Drug: Empagliflozin 10 MG|Drug: Placebo pills
|
| Outcome Measures: |
Change in liver fat content|Remission of steatosis|Change of liver fat content|Changes of alanine aminotransferase (ALT)|Changes of aspartate aminotransferase (AST)|Changes of alkaline phosphatase (ALP)|Changes of gamma glutamyl transferase (GGT)|Changes of fasting glucose|Changes of haemoglobin A1c (HbA1c)|Changes of total cholesterol|Changes of low density lipoprotein (LDL)|Changes of high density lipoprotein (HDL)|Changes of body weight|Changes of height|Changes of body mass index (BMI)|Changes of waist circumference|Changes of systolic blood pressure|Changes of diastolic blood pressure
|
| Sponsor/Collaborators: |
The University of Hong Kong|Food and Health Bureau, Hong Kong
|
| Gender: |
All
|
| Age: |
18 Years to 80 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 4
|
| Enrollment: |
98
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
January 1, 2021
|
| Completion Date: |
December 31, 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
April 28, 2021
|
| Locations: |
The University of Hong Kong/Queen Mary Hospital, Hong Kong, Hong Kong, China, Hong Kong
|
| URL: |
https://ClinicalTrials.gov/show/NCT04642261
|
